Evommune and Axceread Drug Discovery Partner start a collaboration on a PKC[theta] Program to kick off Evommune’s inflammation pipeline

LOS ALTOS, CALIFORNIA and FUJISAWA, Japan, Dec 10, 2020 / PRNewswire / – Evommune, Inc., a privately held R&D company and driver of innovation in chronic inflammation, and Axcelead Drug Discovery Partners, Inc. (Axcelead), a Japanese drug discovery solutions provider, today announced the start of an exclusive partnership late discovery program. The goal of the program will be to identify a potent and highly specific PKCtheta inhibitor that could have broad utility in a range of inflammatory diseases. The PKCtheta program comes from Axceread’s Hit-Identified Target (A-HiT) project. As part of this program, Evommune and Axceread will continue to conduct joint lead optimization research.

“This program lays the foundation for our new pipeline and is in line with our goal of offering new treatment options to patients with chronic inflammatory diseases,” said Luis Peña, President and CEO of Evommune. “We are impressed with the progress Axceread has made on this program, which enables Evommune to identify multiple molecules for clinical development.”

“The overactivation of effector T cells and the failure of anti-inflammatory regulatory T cells to control this response are at the core of many chronic inflammatory diseases,” said Hans Hofland, Senior Vice President, Research. “Inhibiting PKCtheta suppresses effector T cells while activating regulatory T cells. This dual role in T cell biology makes PKCtheta an extremely attractive target for the treatment of a wide range of inflammatory diseases.”

“Our mission is to be the best partner for people involved in drug discovery, contributing to the discovery of innovative drugs based on the technology and know-how we have gained through our research in the pharmaceutical industry, and the vast Amount of drug discovery data we’ve gathered, “said Yoshinori Ikeura, CEO of Axceread. “We are excited to work with Evommune to add to their new pipeline and deliver a therapeutic drug to patients with inflammatory disease as soon as possible.”

About PKCtheta

PKCtheta, a member of the protein kinase C (PKC) kinase family, is primarily expressed in T cells and plays a dual role in T cell biology. First, activation of PKCtheta leads to effector T cell activation, proliferation and production of IL-2. Second, the inhibition of PKCtheta (genetic knockouts or pharmacological inhibition) leads to an increase in both the number and functionality of regulatory T cells. Mice lacking functional PKCtheta are very resistant to inflammatory diseases. Genetic variants within the gene for PKCtheta have been implicated in many inflammatory diseases. Possible indications are rheumatoid arthritis, asthma, psoriasis, atopic dermatitis and Crohn’s disease.

About Evommune, Inc.

Evommune is a privately held R&D company and engine of innovation in chronic inflammation. The company is taking a tissue-based approach to discovering and accelerating transformative drug development in inflammatory diseases. Evommune was founded in 2020 by a successful and experienced leadership team focused on building a robust pipeline of unique therapies to help patients with chronic inflammatory diseases. The company is based in The big ones, California. More information is available at Evommune.com.

About Axceread Drug Discovery Partners, Inc.

Axceread is the first integrated provider of drug discovery solutions for the pharmaceutical industry in Japanafter he replaced the drug discovery research capacity of Takeda Pharmaceutical Company Limited and closed his business on July 1, 2017. The company offers integrated services, from the discovery of drug targets to the optimization of small and medium-molecular drug candidates, in which the company has particular expertise, to bridging the gap to clinical development. The A-HiT project is a library of potential drug candidates and optimized scoring systems for a variety of drug targets. Please visit https://www.axcelead.com/en/ for more information.

Media contact for Evommune, Inc .:

Sheryl Seapy
+ 1-949-903-4750
E-mail: [email protected]
URL: Evommune.com

Media contact for Axceread Drug Discovery Partners, Inc.

Sales and marketing
+ 81-80-7005-5100
E-mail: [email protected]
URL: https://www.axceread.com/en/

SOURCE Evommune, Inc.